Connect with us


Strides Pharma receives approval from USFDA for antidepressant medication



Strides Pharma gets USFDA nod for antidepressant medication, ET HealthWorld

New Delhi: Strides Pharma Science announced that its subsidiary has received approval from the US Food & Drug Administration (USFDA) to market a generic antidepressant medication. The company’s Singapore-based subsidiary, Strides Pharma Global Pte Ltd, has been granted approval for Fluoxetine Tabs (10 and 20 mg), which is therapeutically equivalent to Eli Lilly’s Prozac tablets. The market size for Fluoxetine tablets is estimated to be USD 23.9 million, according to IMS.

This approval will enhance the company’s presence in the Fluoxetine portfolio, alongside the existing approval of Fluoxetine capsules, which have a market size of USD 106 million. Fluoxetine is commonly used for the treatment of major depressive disorder (MDD) and Obsessive Compulsive Disorder (OCD), among other conditions.

The approval from the USFDA signifies a significant milestone for Strides Pharma Science, consolidating its position in the generic pharmaceutical market. The company’s focus on expanding its product portfolio and gaining regulatory approvals underscores its commitment to providing affordable and accessible healthcare solutions to patients in need.

The approval of Fluoxetine Tabs adds to the company’s growing list of generic medications and reinforces its reputation as a reliable supplier of high-quality pharmaceutical products. With this latest development, Strides Pharma Science is set to further solidify its presence in the global pharmaceutical industry and contribute to improving healthcare outcomes worldwide.

Click to comment

You must be logged in to post a comment Login

Leave a Reply